Fair-Value Report — HighTide Therapeutics (2511.HK)

Insider Signal

Verified Snapshot

All HKD figures converted from CNY at ~1.073 HKD/CNY unless stated. Financials reported in RMB. Cash figure is an estimate: FY2025 year-end cash CNY 503M ≈ HKD 540M, plus net placing proceeds of ~HKD 225M (99M × HKD 2.28), less ~HKD 133M burn Jan–Jul 2026.

Business Overview

HighTide Therapeutics is a clinical-stage biopharmaceutical company focused on multi-target metabolic and liver disease therapies, headquartered in Shenzhen, China. It listed on the HKEX Main Board on 22 December 2023. The company's platform is anchored on HTD1801, a berberine-ursodeoxycholic acid (BUDCA) conjugate designed to simultaneously address insulin resistance, lipid dysregulation, hepatic inflammation, and kidney injury — a multi-pathway approach targeting what it calls Cardio-Kidney-Metabolic (CKM) diseases.

Pipeline Summary

The T2DM NDA acceptance is the single most important catalyst: China's NMPA accepted HighTide's first-ever NDA for HTD1801 in T2DM in March 2026, following three positive Phase III trials. The Phase III SYMPHONY-2 study was published in NEJM Evidence (June 2026), a prestigious peer-reviewed journal that significantly raises the international profile of HTD1801's clinical evidence base. HTD1801 demonstrated improvements across glycaemic control, insulin sensitivity, lipid lowering, renal protection, and body weight — a multi-benefit profile that positions it as potentially complementary to GLP-1 agonists in the China market.

Valuation — Method & Approach

Method: Risk-adjusted NPV (pipeline rNPV) + net cash. This is the appropriate framework for a clinical-stage company with zero revenue. A DCF on current cashflows is meaningless; the value resides in the probability-weighted present value of future drug revenues. We supplement with a peer comparison anchored on Hua Medicine (2552.HK), the most directly comparable HK-listed T2DM company.

T2DM rNPV Assumptions

• China antidiabetic drug market: ~USD 7B/year (~HKD 55B/year), growing ~8% p.a.
• HTD1801 peak market share: 0.5% (bear) / 1.5% (base) / 2.5% (bull)
• Peak revenues: HKD 275M / HKD 825M / HKD 1,375M per annum
• Operating margin at maturity: 45%
• Peak FCF: HKD 124M / HKD 371M / HKD 619M
• Expected approval: bear Q1 2030 / base Q2 2028 / bull Q2 2027
• Revenue-stream duration: 10 years from launch
• Discount rate: 13% (clinical-stage HK biotech)
• Approval probability: 45% (bear) / 70% (base) / 80% (bull)

Scenario Valuation Table (HKD per share)

Net cash in bull/base reduced from HKD 633M (Jul 2026 estimate) by additional burn to modelled approval date. Bear scenario includes a 15% dilution haircut for an assumed additional capital raise needed if approval slips to 2030.

Reverse Read

At HKD 3.35, the market is implying an enterprise value for the pipeline of ~HKD 1,310M. On our base-case framework, this requires either (a) a ~72% NDA-to-approval conversion rate (slightly above our 70% base) combined with ~1.5% peak market share, or (b) ~70% probability with ~1.7% peak share. Either is achievable given the positive Phase III data and NEJM publication. The current price is therefore roughly fair on base assumptions — upside is contingent on bull-case commercial outcomes, not on further de-risking of the approval pathway itself.

Peer Comparison

Market caps verified via Investing.com / companiesmarketcap.com as at August 2026. CStone and Akeso included for reference only; they are not directly comparable metabolic-disease peers. Hua Medicine is the closest peer — both HK-listed, both China T2DM-focused. HighTide at HKD 1.91B vs Hua Medicine at HKD 2.61B represents a 27% discount to an approved-drug peer, which looks modest given HighTide's NDA is merely accepted (not yet approved) but has a superior clinical-evidence profile (NEJM Evidence publication) and a broader multi-indication pipeline. If approved, HighTide should trade at or above Hua Medicine's valuation, implying ~HKD 2.61B–3.0B market cap = HKD 4.56–5.25/share.

Conclusion

Rating: Speculative Buy. The base-case fair value of HKD 3.60 is modestly above the current price of HKD 3.35, and the peer-anchored analysis (approved T2DM comparable at HKD 2.61B market cap) suggests HighTide is appropriately priced for a pre-approval stage but offers meaningful re-rating potential on the upside. The insider signal — Zhang Xiaolei buying HKD 35M at open-market prices 54% above the just-completed placing price — is a genuine conviction signal from a double-digit shareholder. The company is well-capitalised through the NMPA review with ~2.6 years of runway. The NEJM Evidence publication and NDA acceptance are genuine milestones, not just marketing.

The rating is "Speculative" rather than "Moderate Buy" for two reasons: (1) the base case barely clears current price — upside requires commercial success, not just approval; and (2) the MASH programme quality issues inject uncertainty into the secondary pipeline. Investors must be comfortable with binary drug-approval risk.

Key Risks

• NMPA approval denial or delay. Even with positive Phase III data, China NMPA reviews can be protracted (12–24+ months post-NDA acceptance). A delay to 2030 materially impairs value (see bear scenario).
• Commercial execution. The China T2DM market is intensely competitive (metformin generics, DPP-4 inhibitors, GLP-1s including domestic semaglutide generics). Peak market share of 1.5% is not guaranteed; pricing and reimbursement (NRDL inclusion) are key uncertainties.
• MASH trial quality issues. Phase IIb data flagged in February 2026 could invalidate or delay the MASH programme. MASH has a high global failure rate; HighTide's programme must be treated as highly speculative.
• Dilution risk. At ~HKD 245M annual cash burn and ~2.6 years of runway, HighTide may need to raise capital before profitability (expected 2030 at the earliest on base case). Additional placings at discounts are probable.
• Filer identity uncertainty. Zhang Xiaolei is not identified as a named director or executive in public filings accessed for this report. His full identity and investment motive remain partially opaque, limiting the signal's interpretive confidence.
• Zero revenue. This is a pure binary-outcome investment; no revenue backstop. Market sentiment towards loss-making HK biotech has been volatile.
• Small-cap liquidity. At HKD 1.91B market cap, institutional capacity to enter/exit is limited. Bid-ask spreads can widen sharply on adverse news.

Sources

• HKEX Disclosure of Interests — 2511.HK, DI event 13 August 2026 (reason code 1101, Zhang Xiaolei filer)
• HKEX Announcement — HighTide Therapeutics placing of 99M shares at HKD 2.28, 31 July 2026 (hkexnews.hk/listedco/listconews/sehk/2026/0731/2026073101999.pdf)
• Investing.com — 2511.HK price HKD 3.35, shares 571.33M (17 Aug 2026)
• Stockopedia — 2511.HK balance sheet: cash CNY 503M, equity CNY 307M, liabilities CNY 244M (FY2025)
• HighTide Therapeutics corporate website — NDA acceptance announcement, 10 March 2026; NEJM Evidence publication, 8 June 2026; ADA 2026 presentation, 6 June 2026
• Tipranks — H1 2025 net loss HKD 129M; NMPA NDA news summary
• Investing.com — Hua Medicine 2552.HK: price HKD 2.61, cap HKD 2.61B, shares 997M (17 Aug 2026)
• companiesmarketcap.com — Akeso 9926.HK market cap HKD 76.73B (Jun 2026)
• WebSearch (TipRanks aggregation) — CStone Pharmaceuticals 2616.HK market cap HKD 11.92B (Jul 2026)
• HKEX Annual Report 2024 (HighTide) — filed 28 March 2025; PDF binary, substantive text not extractable via automated fetch